Healthcare and research teams are scaling synthetic data with LLMs, but evaluation, provenance, and labeling standards are still behind the pace of adoption. New reviews and policy guidance converge on the same message: without transparent validation and governance, synthetic datasets will be hard to trust in clinical and scientific workflows.
A Scoping Review of Synthetic Data Generation by Language Models in Biomedical Research
An arXiv scoping review analyzed 59 studies (2020–2025) on LLM-driven synthetic data generation in biomedical settings. Prompt-based generation dominates (74.6%), and unstructured text is the main modality (78%), underscoring how quickly teams are using LLMs to stand up “good enough” datasets for prototyping and analysis. The authors flag persistent gaps in standardized evaluation protocols and call for transparent frameworks to support clinical adoption.
- Data leads should expect auditors and IRBs to ask for repeatable utility and risk evaluations, not just model outputs.
- Heavy reliance on prompt-based methods raises reproducibility questions (prompt drift, model versioning, sampling settings).
- Text-first synthetic data may not translate cleanly to structured EHR or imaging use cases without separate validation.
Synthetic Data: The New Data Frontier
The World Economic Forum’s September 2025 report frames synthetic data as a response to scarcity, privacy constraints, and representativeness gaps across sectors. It also highlights governance risks, including data integrity concerns and “model collapse,” and offers recommendations for developers, organizations, and regulators. For practitioners, this reads less like a technical playbook and more like a checklist of controls that will show up in procurement and oversight.
- Founders selling synthetic data tooling should map product features to governance expectations (documentation, controls, accountability).
- Compliance teams can use the report to benchmark policies on access controls, disclosure, and risk management.
Synthetic Data in Health Economics and Outcomes Research
A peer-reviewed HEOR-focused article reviews how synthetic data can help with privacy barriers, limited sample sizes, and inclusion of underrepresented populations—especially in rare disease research. It emphasizes that HEOR needs evaluation frameworks tailored to its endpoints and decision contexts, rather than borrowing generic ML metrics. The takeaway: domain fit matters as much as privacy claims.
- HEOR teams should define “utility” in terms of downstream economic/outcomes analyses, not only statistical similarity.
- Regulatory-facing work will likely require context-specific validation plans and clear limitations statements.
SynthLLM: Breaking the AI 'Data Wall' with Scalable Synthetic Data
Microsoft Research Asia introduced SynthLLM, positioned as a scalable way to generate synthetic training data from pretraining corpora across domains including healthcare, autonomous driving, education, and code generation. The key operational promise is scale without manual labeling, which targets a major bottleneck for teams training or fine-tuning models. The open question for adopters is how to document provenance and measure quality when synthetic data is derived from large, heterogeneous corpora.
- Engineering teams should plan for dataset lineage: source corpora, transformations, and generation parameters.
- “No labeling” shifts effort to evaluation—task performance, bias checks, and leakage testing become the cost center.
- Sector-specific constraints (healthcare, driving) will demand stronger assurance than generic benchmarks.
GenAI Synthetic Data Create Ethical Challenges for Scientists
A PNAS study spotlights integrity and ethics risks when GenAI-generated synthetic data is misrepresented as real, potentially undermining reproducibility. The paper argues for transparency and validation standards to prevent scientific record contamination. For labs and platforms, the practical issue is governance: labeling, disclosure, and review processes that keep synthetic artifacts from silently entering analyses.
- Research orgs should implement clear labeling and disclosure policies for synthetic datasets and figures.
- Publishers and funders may tighten requirements on provenance and validation, raising the bar for submissions.
- Data integrity controls (audit trails, checks) become as important as privacy preservation.